Fevertree Drinks

Kepler Cheuvreux has upgraded Fever Tree from "hold" to "buy" and raised the price target from 900 to 910 pence. Analysts cite accelerated growth in the US, improved earnings transparency and a stabilised UK market as reasons for the upgrade. Kepler also raised EBITDA and EPS estimates for 2026/2027 and sees freer cash flow for dividends and share buybacks. The stock then rose by around 4.2% to 828 pence. » Plus sur de.investing.com

Fevertree reports currency‑adjusted brand revenue growth of 8% in the first half of 2026 and increased US growth of 11%, while products beyond tonic water now make up almost half of revenue. Adjusted EBITDA margin improved by 20 basis points to 10.9% and normalized EPS rose 5%. Management expects US growth to accelerate in H2, plans local US production and forecasts free cash flow of at least £100m for 2027/28; nonetheless the stock fell 5.13% in pre-market trading. » Plus sur de.investing.com

Laura Hagan will step down from her mandate as a non-executive director at Fevertree Drinks at the end of July. She had served on the board since May 2021, was chair of the remuneration committee and a member of the audit and nomination committees. After her departure, David Lapp will assume the chair of the remuneration committee. » Plus sur de.investing.com